Digital Transformation Consulting

Biogen, a leader in biotechnology focused on neurological and neurodegenerative conditions, faced limitations in drug discovery due to the constraints of classical computing, which could only handle molecular comparisons up to a certain size. To address this challenge, Accenture Labs collaborated with 1QBit to leverage quantum computing capabilities, which allow for the comparison of much larger molecules. This collaboration involved adapting a pre-developed structural molecular comparison algorithm and cloud-based API to meet Biogen’s specific pharmacophore requirements.

The tailored solution resulted in a breakthrough where the quantum-enabled method for molecular comparison was validated to be as effective, if not superior, to existing classical methods. This advancement suggests that quantum computing could significantly enhance the drug discovery process, ultimately improving patient outcomes. The collaboration identified quantum-enabled optimization processes that could provide Biogen with deeper insights into molecular interactions, thereby expediting drug discovery.

In just over two months, the partnership progressed from initial discussions to a proof of concept and then to an enterprise-ready quantum-enabled application. This application not only generates molecular comparison results but also offers deeper insights into shared traits among molecules. By integrating this quantum-enabled application with traditional methods, Biogen gained a competitive advantage through reduced time to market and cost savings, enabling them to conduct more comprehensive analyses of millions of molecules efficiently.